Workflow
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
CLRBCellectar Biosciences(CLRB) GlobeNewswire News Room·2024-07-22 10:40

The new warrants purchased by investors include Tranche A, B and C. The Tranche A warrants provide gross proceeds up to approximately 17.0millionbasedontheexercisepriceof17.0 million based on the exercise price of 2.52, which was the closing market price of the Company's common stock on July 19, 2024, and include a 10-trading-day trigger for exercise following Cellectar's public announcement of the Food and Drug Administration (FDA) having assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131. The Tranche B Warr ...